Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. [PDF]
Clin Transl SciKim JD +4 more
europepmc +1 more source
Development and Validation of Bioanalytical Method for Efavirenz in Dried Blood Spot Using High Performance Liquid Chromatography-Photodiode Array. [PDF]
J Exp PharmacolPutri DN, Harahap Y, Saputri FA.
europepmc +1 more source
Late-Onset Efavirenz-Induced Liver Toxicity in a 17-Year-Old, Filipino, Patient With HIV. [PDF]
ACG Case Rep JClutario JDC +5 more
europepmc +1 more source
Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole. [PDF]
CPT Pharmacometrics Syst PharmacolAl-Amiry Santos LG, Polak S, Yeo KR.
europepmc +1 more source
Determinants and outcomes of adverse drug reactions among people living with HIV on antiretroviral therapy in Nigeria. [PDF]
BMC Infect DisEtuk VP +3 more
europepmc +1 more source
Efavirenz-Induced Hepatitis Mimicking Autoimmune Hepatitis: A Case Report. [PDF]
CureusChowdhury AH +4 more
europepmc +1 more source
Spatial and temporal variability and distribution of emerging contaminants in South African freshwater and wastewater. [PDF]
Sci RepDikobe PI +3 more
europepmc +1 more source
Efficacy and safety of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) versus efavirenz, lamivudine, and tenofovir disoproxil fumarate (EFV+3TC + TDF) in late-presenting people with HIV rapid initial antiretroviral therapy. [PDF]
BMC Infect DisLi Q +6 more
europepmc +1 more source
Pharmacogenetics in Tuberculosis-HIV Coinfected Populations: A Systematic Review of Genetic Variants Influencing Antiretroviral and Anti-Tuberculosis Drug Response. [PDF]
J Multidiscip HealthcHardi H +3 more
europepmc +1 more source
Correction: Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome. [PDF]
PLoS OneNightingale S +4 more
europepmc +1 more source